• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR Raises Second Tender Offer Price for FUJI SOFT to 9,850 Yen Per Share

    2/4/25 9:09:00 AM ET
    $KKR
    Investment Managers
    Finance
    Get the next $KKR alert in real time by email

    Increased tender offer price aims to resolve uncertainty around FUJI SOFT's privatization and enable KKR to focus on value creation efforts alongside the Company post privatization

    KKR, a leading global investment firm, announced today that in connection with the Second Tender Offer in its two-stage tender offer scheme (the "Tender Offer") for the common shares and share options of FUJI SOFT INCORPORATED ("FUJI SOFT" or the "Company"; TSE stock code 9749) through FK Co., Ltd. (the "Offeror" or "FK Co."), an entity owned by investment funds managed by KKR, the Offeror has submitted an amendment statement to the Tender Offer Registration Statement that was submitted on November 20, 2024 (including the matters amended in the amendment statements to the Tender Offer Registration Statement submitted on December 19, 2024, January 9, 2025 and January 24, 2025) (the "Amendment Statement").

    The Offeror has decided to increase the tender offer price for the Second Tender Offer to 9,850 yen per share from 9,451 yen per share, and 1,277,000 yen per 5th Series Share Option, 1,139,600 yen per 6th Series Share Option, 333,100 yen per 7th Series Share Option. The tender offer period has also been extended by seven business days to February 19, 2025.

    Rationale for Increased Tender Offer Price

    The increased tender offer price considers FUJI SOFT's elevated share price, which has stayed above the previous Second Tender Offer price of 9,451 yen per share and the announced tender offer price of 9,600 yen per share by Bain Capital, which has yet to commence its tender offer. It also considers the fact that FUJI SOFT's share price has not declined as expected despite there being no competing tender offer for an extended period. Given that any further prolonged uncertainty around FUJI SOFT's privatization will hurt the Company and its stakeholders, including employees and customers, KKR has decided to raise the Second Tender Offer price to minimize the uncertainty and accelerate FUJI SOFT's privatization, and turn its focus to value creation efforts alongside the Company.

    The increased Second Tender Offer Price of 9,850 yen represents a premium of:

    • 0.51% on the closing price of the Company Shares on the Prime Market of the Tokyo Stock Exchange on February 3, 2025 (9,800 yen), the business day immediately preceding the submission of the Amendment Statement;
    • 33.29% on the closing price on August 7, 2024 (7,390 yen), the business day immediately preceding the announcement of the implementation of the First Tender Offer by the Offeror;
    • 38.15% on the simple average of the closing price of the Company shares for a period of 1 year until August 7, 2024 (7,130 yen);
    • 44.92% of the simple average of the closing price of the Company shares for a period of 3 months until August 7, 2024 (6,797 yen); and
    • 51.42% of the simple average of the closing price of the Company shares for a period of 6 months until August 7, 2024 (6,505 yen).

    The Offeror believes these premiums are satisfactory for shareholders and share option holders. Given the increased price, the Offeror believes that the prospects of the Second Tender Offer succeeding have increased sufficiently such that it does not need to launch a new tender offer after the Second Tender Offer.

    The Offeror plans to continue to offer the opportunity for financial compensation to within the range of the previously announced make-whole amount (651 yen per share) to the shareholders and share option holders who tendered into the First Tender Offer ("Former Shareholders"), and while details regarding the timeframe and method continue to be under consideration, the Offeror plans to notify all Former Shareholders eligible for this compensation as soon as the details are finalized. Additionally, the Offeror plans to begin contacting Former Shareholders eligible for this compensation within a month after the Second Tender Offer is successfully completed. At the same time, the Offeror will post contact information for inquiries regarding this compensation on the KKR website (https://www.kkr.com/jp/ja), and any Former Shareholders eligible for this compensation should use this contact information for inquiries if they have not heard from the Offeror.

    For details on the Amendment Statement, please refer to the release issued by the Offeror today titled "(Amendment) Notice Regarding Amendment to "Notice Regarding the Commencement of Tender Offer for the Shares of FUJI SOFT INCORPORATED (Securities Code: 9749) by FK Co., Ltd." Following Submission of Amendment Statement to the Tender Offer Registration Statement by FK Co., Ltd." (the "Amendment Release").

    ***

    This press release should be read in conjunction with the Amendment Release.

    The purpose of this press release is to publicly announce an extension to the tender offer period for the Second Tender Offer and it has not been prepared for the purpose of soliciting an offer to sell or purchase in the Tender Offer. When making an application to tender, please be sure to read the relevant Tender Offer Explanatory Statement for the Tender Offer and make your own decision as a shareholder or share option holder. This press release does not constitute, either in whole or in part, a solicitation of an offer to sell or purchase any securities, and the existence of this press release (or any part thereof) or its distribution shall not be construed as a basis for any agreement regarding the Tender Offer, nor shall it be relied upon in concluding an agreement regarding the Tender Offer.

    The Tender Offer will be conducted in compliance with the procedures and information disclosure standards set forth in Japanese law, and those procedures and standards are not always the same as the procedures and information disclosure standards in the U.S. In particular, neither sections 13(e) or 14(d) of the U.S. Securities Exchange Act of 1934 (as amended; the same shall apply hereinafter) or the rules under these sections apply to the Tender Offer; and therefore the Tender Offer will not be conducted in accordance with those procedures and standards.

    Unless otherwise specified, all procedures relating to the Tender Offer are to be conducted entirely in Japanese. All or a part of the documentation relating to the Tender Offer will be prepared in English; however, if there is any discrepancy between the English-language documents and the Japanese-language documents, the Japanese-language documents shall prevail.

    This press release includes statements that fall under "forward-looking statements" as defined in section 27A of the U.S. Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934. Due to known or unknown risks, uncertainties or other factors, actual results may differ materially from the predictions indicated by the statements that are implicitly or explicitly forward-looking statements. Neither the Offeror nor any of its affiliates guarantee that the predictions indicated by the statements that are implicitly or expressly forward-looking statements will materialize. The forward-looking statements in this press release were prepared based on information held by the Offeror as of today, and the Offeror and its affiliates shall not be obliged to amend or revise such statements to reflect future events or circumstances, except as required by laws and regulations.

    The Offeror, its financial advisors and the Tender Offer agent (and their respective affiliates) may purchase the common shares and share options of FUJI SOFT, by means other than the Tender Offer, or conduct an act aimed at such purchases, for their own account or for their client's accounts, in the scope of their ordinary business and to the extent permitted under financial instrument exchange-related laws and regulations, and any other applicable laws and regulations in Japan, in accordance with the requirements of Rule 14e-5(b) of the U.S. Securities Exchange Act of 1934. Such purchases may be conducted at the market price through market transactions or at a price determined by negotiations off-market. In the event that information regarding such purchases is disclosed in Japan, such information will also be disclosed on the English website of the person conducting such purchases (or by any other method of public disclosure).

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250204314392/en/

    For more information, please contact:

    Media Contact

    KKR Asia Pacific

    Wei Jun Ong

    +65 6922 5813

    [email protected]

    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR

    DatePrice TargetRatingAnalyst
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    1/14/2026$131.00Buy → Hold
    TD Cowen
    12/11/2025$176.00Buy
    UBS
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    6/30/2025$150.00Overweight
    Piper Sandler
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KKR
    SEC Filings

    View All

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    3/2/26 8:32:24 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:01:59 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form DEFA14A filed by KKR & Co. Inc.

    DEFA14A - KKR & Co. Inc. (0001404912) (Filer)

    2/27/26 5:00:39 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Kkr Group Partnership L.P.

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/10/26 5:15:24 PM ET
    $KKR
    Investment Managers
    Finance

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Group Partnership L.P. sold $807,546,115 worth of shares (19,715,000 units at $40.96), disposed of 402,773 shares and gifted 81,213 shares (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    3/4/26 7:46:52 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Share

    KKR Income Opportunities Fund (the "Fund") (NYSE:KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fund's current share price of $11.04 per share (as of market close on March 9, 2026), the distributions represent an annualized distribution rate of 13.21%, (calculated by annualizing the distribution amount and dividing it by the current price). The monthly distribution schedule is as follows for the months of April, May, and June: Ex-Date: April 10, 2026 Record Date: April 10, 2026 Payable Date: April 30, 2026     Ex-Date: May 8, 2026 Record Date:

    3/10/26 5:23:00 PM ET
    $KIO
    $KKR
    Investment Managers
    Finance

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    KKR to Present at the 2026 RBC Capital Markets Financial Institutions Conference

    KKR & Co. Inc. (NYSE:KKR) announced today that Robert H. Lewin, Chief Financial Officer, will present at the 2026 RBC Capital Markets Financial Institutions Conference on Wednesday, March 11, 2026 at 9:20AM ET. A live webcast of the presentation will be available on the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. For those unable to listen to the live webcast, a replay will be available on the website shortly after the event. Any questions regarding the webcast may be addressed to KKR's Investor Relations team at [email protected]. ABOUT KKR KKR is a leading global investment firm that offers alternative asset management as well as

    2/26/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    Peak Re Welcomes KKR and Quadrantis Capital as Minority Investors

    Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden

    10/20/25 9:05:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Appoints Craig Arnold to Board

    KKR & Co. Inc. (NYSE:KKR) today announced that Craig Arnold has been appointed to the Board of Directors effective September 23, 2025. His appointment will bring the number of independent directors to eleven out of a total of fifteen Board seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924641078/en/Craig Arnold Mr. Arnold is the former Chairman and Chief Executive Officer of Eaton Corporation, a global intelligent power management company. KKR's other Board members are: Henry Kravis (Co-Founder and Co-Executive Chairman of KKR), George Roberts (Co-Founder and Co-Executive Chairman of KKR), Joseph Bae (Co-Executive Of

    9/24/25 4:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Financials

    Live finance-specific insights

    View All

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2025 Results; Declares First Quarter 2026 Distribution of $0.48 per Share

    PHILADELPHIA and NEW YORK, Feb. 25, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK), or the Company, today announced its financial and operating results for the quarter and year ended December 31, 2025, and that its board of directors has declared a first quarter 2026 distribution of $0.48 per share. Financial and Operating Highlights for the Quarter Ended December 31, 2025(1)Net investment income of $0.48 per share, compared to $0.57 per share for the quarter ended September 30, 2025Adjusted net investment income(2) of $0.52 per share, compared to $0.57 per share for the q

    2/25/26 4:15:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    Keurig Dr Pepper Announces Updated Financing Plan for JDE Peet's Acquisition

    Company strengthens balance sheet by further reducing projected leverage and attracts additional high-quality investorsBURLINGTON, Mass. and FRISCO, Texas, Feb. 23, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP, ", the Company", )) today announced updated financing plans and transaction timelines for the acquisition of JDE Peet's and subsequent planned separation into two independent companies ("Beverage Co." and "Global Coffee Co." pending the announcement of official corporate names).Key developments include:A targeted close of the JDE Peet's acquisition in early April 2026, with expected combined net leverage of approximately 4.5x1An agreement to upsize the previously announced B

    2/23/26 4:30:00 PM ET
    $APO
    $KDP
    $KKR
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples